Molecular Partners Ag (MOLN) EBT (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly EBT of -$16784.9 for Q1 2026, up 10.02% year-over-year from -$15255.9 in Q1 2025, and up 99.98% quarter-over-quarter from -$81.8 million in Q4 2025.
Molecular Partners Ag (MOLN) EBT (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EBT for 7 consecutive years, with -$16784.9 the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 10.02% year-over-year to -$16784.9; the TTM figure through Mar 2026 stood at -$81.9 million (down 31.54% YoY), while the FY2025 annual figure was -$81.9 million, down 31.56% from the prior year.
- EBT climbed to -$16784.9 in Q1 2026 per MOLN's latest filing, from -$81.8 million in the prior quarter.
- Across five years, EBT topped out at $127.7 million in Q4 2022 and bottomed at -$81.8 million in Q4 2025.
- Historically, EBT has averaged -$6.5 million across 5 years, with a median of -$16784.9 in 2026.
- Annual changes were most pronounced in 2022 — EBT surged 1005.57% — and 2023, when it sank 278.7%.
- Molecular Partners Ag's EBT stood at $127.7 million in 2022, then sank by 156.44% to -$72.1 million in 2023, then increased by 13.69% to -$62.2 million in 2024, then sank by 31.56% to -$81.8 million in 2025, then soared by 99.98% to -$16784.9 in 2026.
- Business Quant data shows MOLN's EBT at -$16784.9 in Q1 2026, -$81.8 million in Q4 2025, and -$14796.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | -16,784.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,784.95 |
| Dec 31, 2025 | -81.84 Mn |
| Sep 30, 2025 | -14,796.30 |
| Jun 30, 2025 | -24,638.54 |
| Mar 31, 2025 | -18,654.67 |
| Dec 31, 2024 | -62.21 Mn |
| Sep 30, 2024 | -18,933.62 |
| Jun 30, 2024 | -16,677.58 |
| Mar 31, 2024 | -12,974.85 |
| Dec 31, 2023 | -72.07 Mn |
| Sep 30, 2023 | -12,950.69 |
| Jun 30, 2023 | -17.78 Mn |
| Mar 31, 2023 | -15,977.42 |
| Dec 31, 2022 | 127.71 Mn |
| Sep 30, 2022 | -13,794.35 |
| Jun 30, 2022 | -4.70 Mn |
| Mar 31, 2022 | 165,807.20 |
| Dec 31, 2021 | -69.12 Mn |
| Sep 30, 2021 | -13,406.09 |
| Jun 30, 2021 | -36.79 Mn |